Candidate microRNAs as prognostic biomarkers in heart failure: A systematic review

Data de publicação: Data Ahead of Print:

Autores da FMUP

  • Joaquim Adelino Correia Ferreira Leite Moreira

    Autor

  • Jennifer Mâncio Silva

    Autor

  • Carmen Dulce Da Silveira Brás Silva Ribeiro

    Autor

Participantes de fora da FMUP

  • Figueiredo, R
  • Adao, R

Unidades de investigação

Abstract

Background: Heart failure (HF) is a high prevalent syndrome with significant burden worldwide. B-type natriuretic peptide (BNP) and N-terminal proBNP are the gold standard biomarkers in HF management. Although useful in clinical practice, they have limitations as their expression can be influenced by ventricular function, aging, obesity, renal failure and atrial arrhythmias. MicroRNAs have recently emerged as potential diagnostic and prognostic biomarkers, given that they are related to cell growth, proliferation, differentiation, and metabolism. An increas-ing amount of research has highlighted some microRNAs for their potential as HF biomarkers. However, different study designs, methods and study groups have led to inconsistent results.Methods and results: We performed a systematic search of available literature on Pubmed and Scopus reporting the prognostic value of microRNAs in HF, followed by a review of risk of bias, according to Quadas Group Standards. Simultaneously, microRNAs' potential as differential diag-nosis and severity biomarkers was also analyzed. Studies have described circulating microRNA as potential diagnostic, prognostic, and severity markers. Mir-622,-519 and-499 were signifi-cantly related to HF with reduced ejection fraction, whereas miR-22-3p revealed greater ability as a severity biomarker. Let-7i-5p, miR-223-5p, miR-423-5p, miR-21, miR-1306-5p and miR-122 serum expressions presented a consistent correlation with HF prognosis. Furthermore, identi-fied miR targets were associated with signaling pathways already known to be involved in HF progression.Conclusion: Several miRs were related to HF pathophysiology and demonstrated potential as biomarkers for disease progression. MicroRNAs have a promising role in HF, and although unques-tionable, we require a deeper and broader understanding of their role and function for future research.(c) 2022 Sociedade Portuguesa de Cardiologia. Published by Elsevier Espan tilde a, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Copyright © 2022 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. All rights reserved.

Dados da publicação

ISSN/ISSNe:
0870-2551, 2174-2030

Revista Portuguesa de Cardiologia  Sociedade Portuguesa De Cardiologia

Tipo:
Review
Páginas:
865-885
Link para outro recurso:
www.scopus.com

Citações Recebidas na Web of Science: 4

Citações Recebidas na Scopus: 8

Documentos

  • Não há documentos

Filiações mostrar / ocultar

Keywords

  • Heart failure; Biomarkers; Prognosis; MicroRNA; Circulating microRNA

Financiamento

Proyectos asociados

Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684

Investigador Principal: João Pedro Melo Marques Pinho Ferreira

Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022

Estudo do tratamento da doença valvular aórtica.

Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira

Estudo Observacional Académico (AORTA) . UniC . 2019

Eficácia da transposição de um pedículo adiposo pericárdico sobre o enfarte de miocárdio em pacientes (ensaio AGTP II)

Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira

Ensaio Clínico Académico (Ensaio AGTP II) . 2019

Early Dual Antiplatelet Therapy versus Aspirin Monotherapy after Coronary Artery Bypass Surgery: survival and safety outcomes

Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira

Estudo Clínico Académico (Bypass) . 2020

Early and Midterm Outcomes following Aortic Valve Replacement with Mechanical versus Bioprosthetic Valves in Patients aged 50 to 70 Years

Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira

Estudo Clínico Académico (Aortic Valve Replacemen) . 2020

Efeito da terapêutica ß-bloqueadora pré-operatória após cirurgia de revascularização do miocárdio: sobrevida e complicações pós-operatórias

Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira

Estudo Clínico Académico . 2021

Persistent Pulmonary Hypertension of the Newborn: Pathophysiological mechanisms and novel therapeutic approaches

Investigador Principal: Carmen Dulce da Silveira Brás Silva Ribeiro

Estudo Clínico Académico . 2020

"Aortic valve surgery in patients with infective endocarditis: mid-term follow-up of patients treated with the St. Jude medical trifecta™ valve"

Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira

Estudo Clínico Académico . 2022

An overview of circulating pulmonary arterial hypertension biomarkers

Investigador Principal: Carmen Dulce da Silveira Brás Silva Ribeiro

Estudo Clínico Académico . 2022

Heart Failure with preserved ejection fraction: a pharmacotherapeutic update

Investigador Principal: Carmen Dulce da Silveira Brás Silva Ribeiro

Estudo Clínico Académico . 2022

Long-term survival after coronary artery bypass grafting: the relevance of surgical procedures analysed by propensity score methods.

Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira

Estudo Clínico Académico (Arrtery bypass) . 2022

Abdominal Aortic Aneurysm - The Portuguese Case: Specificities and Consequences

Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira

Estudo Clínico Académico . 2022

New Insights into Epidemiology and Pathophysiology of Abdominal Aortic Aneurysms

Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira

Estudo Clínico Académico . 2021

Pthological rola of urocortin-2 in pulmonaryn hypertension - therapeutic implications

Investigador Principal: Carmen Dulce da Silveira Brás Silva Ribeiro

Estudo Clínico Académico . 2020

Impacto clínico e hemodinâmico da substituição cirúrgica da válvula aórtica por biopróteses de última geração

Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira

Estudo Clínico Académico . 2020

Condicionamento isquémico cardíaco remoto como adjuvante da revascularização miocárdia na doença coronário aguda

Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira

Estudo Clínico Académico . 2020

Citar a publicação

Partilhar a publicação